CareDx Completes Orderly Management Transition
CareDx, Inc. (Nasdaq: CDNA) announced the completion of its leadership transition from Peter Maag, PhD, to Reginald Seeto, MBBS, as Chief Executive Officer.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CareDx, Inc. (Nasdaq: CDNA) announced the completion of its leadership transition from Peter Maag, PhD, to Reginald Seeto, MBBS, as Chief Executive Officer. This change marks the end of an orderly transition that began in November 2020, when Maag became Executive Chairman. He will now step down from this role but will remain on the Board of Directors. Michael D. Goldberg, the lead independent Director, will return as independent Chair, a position he previously held from 2011 to 2019. CareDx focuses on precision medicine solutions for transplant patients.
Positive
- Completion of leadership transition may bring fresh perspectives to CareDx.
- Reginald Seeto's appointment signals strategic continuity in executive leadership.
Negative
- None.
Details
News Market Reaction – CDNA
The recorded move for CDNA in the trading session of this news was -2.92%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that the company has completed its transition from Peter Maag, PhD, to Reginald Seeto, MBBS, as Chief Executive Officer.
Concurrent with the appointment of Dr. Seeto as President and Chief Executive Officer of CareDx in November 2020, Dr. Maag had agreed to serve as Executive Chairman of the company’s Board of Directors to facilitate an orderly transition. Now that this transition is complete, Dr. Maag will step down as Executive Chairman but will continue to serve the company as a member of its Board of Directors. Michael D. Goldberg, CareDx’s lead independent Director, will resume his prior role as independent Chair, a position he previously held from 2011 to 2019.
About CareDx
CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.
CONTACTS:
CareDx, Inc.
Sasha King
Chief Marketing Officer
415-287-2393
sking@CareDx.com
Investor Relations
Ian Cooney
(415) 722-4563
investor@CareDx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.